West Pharmaceutical Services, Inc. WST
Set alert
At close · Nov 2
After hours · Nov 2, 4:34 PM ET
- YTD
- +48.24%
- 1 year
- +44.60%
- Open
- 412.89
- Prev close
- 412.62
- Mkt cap
- 28.41B
- Vol
- 1.46M
- Avg vol
- 571.97K
- EPS
- 7.81
- P/E
- 52.23
- Div yield
- 0.25%
More statistics
- Low
- 407.14
- High
- 418.50
- Forward P/E
- 39.53
- Beta
- 1.14
- Short ratio
- 3.38
- Inst. own
- 103.72%
- Dividend
- 1.04
- Ex-div date
- Nov 9, 2026
- Earnings
- Feb 11, 2027
- 50-d avg
- 367.60
- 200-d avg
- 313.38
- 1y target
- 466.67
5Y chart
Events in this range
- Nov 9, 2021Dividend: 0.18
- Nov 10, 2021Dividend: 0.18
- Jan 18, 2022Dividend: 0.18
- Apr 19, 2022Dividend: 0.18
- Jul 19, 2022Dividend: 0.18
- Nov 8, 2022Dividend: 0.19
- Nov 16, 2022Dividend: 0.19
- Jan 24, 2023Dividend: 0.19
- Apr 25, 2023Dividend: 0.19
- Jul 25, 2023Dividend: 0.19
- Nov 7, 2023Dividend: 0.2
- Jan 30, 2024Dividend: 0.2
- Apr 23, 2024Dividend: 0.2
- Jul 31, 2024Dividend: 0.2
- Nov 13, 2024Dividend: 0.21
- Feb 7, 2025Dividend: 0.21
- Apr 30, 2025Dividend: 0.21
- Jul 30, 2025Dividend: 0.21
- Oct 23, 2025Earnings: 1.96; estimate 1.68; surprise 16.67%
- Nov 12, 2025Dividend: 0.22
- Jan 28, 2026Dividend: 0.22
- Feb 12, 2026Earnings: 2.04; estimate 1.83; surprise 11.48%
- Apr 23, 2026Earnings: 2.13; estimate 1.68; surprise 26.79%
- Apr 29, 2026Dividend: 0.22
- Jul 23, 2026Earnings: 2.37; estimate 2.08; surprise 13.94%
- Jul 29, 2026Dividend: 0.22
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 13, 2026Rating: TD Cowen · Buy → Buy
- Oct 29, 2026Earnings: 2.66; estimate 2.2; surprise 20.91%
- Oct 30, 2026Rating: Evercore ISI Group · Outperform → Outperform
- Oct 30, 2026Rating: Barclays · Overweight → Overweight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
- Oct 30, 2026Rating: Citigroup · Buy → Buy
Signals (88)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| SMA: Bullish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| RSI: Oversold | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | May 13, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Feb 12, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 29, 2024 | 2 years ago |
| SMA: Bullish | Jan 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 21, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 24, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| RSI: Overbought | May 1, 2023 | 3 years ago |
| RSI: Overbought | Apr 10, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| RSI: Oversold | Oct 31, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 18, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 28.42B
- Enterprise value
- 28.59B
- Trailing P/E
- 45.79
- Forward P/E
- 39.53
- PEG ratio
- 3.21
- Price / sales
- 8.37
- Price / book
- 9.59
- EPS (TTM)
- 8.91
- Beta
- 1.14
- Dividend yield
- 0.25%
- Payout ratio
- 9.88%
- Profit margin
- 18.81%
- Revenue (TTM)
- 3.40B
- Revenue growth
- 8.70%
- Free cash flow
- 345.56M
- Total cash
- 464.10M
- Total debt
- 313.90M
- Return on equity
- 21.23%
- Shares outstanding
- 69.66M
- Short % of float
- 3.38%
- 50-day average
- 367.60
- 200-day average
- 313.38
Analyst view
Consensus: strong buy
- Target (low)
- 340.00
- Target (mean)
- 466.67
- Target (high)
- 500.00
- Strong buy3
- Buy12
- Hold0
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 2.28.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 2.27 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.20 | 2.66 | +0.46 | +20.91% |
| Jul 23, 2026 | Jun 30, 2026 | 2.08 | 2.37 | +0.29 | +13.94% |
| Apr 23, 2026 | Mar 31, 2026 | 1.68 | 2.13 | +0.45 | +26.79% |
| Feb 12, 2026 | Dec 31, 2025 | 1.83 | 2.04 | +0.21 | +11.48% |
| Oct 23, 2025 | Sep 30, 2025 | 1.68 | 1.96 | +0.28 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Citigroup | main | Buy | Buy |
| Oct 30, 2026 | TD Cowen | main | Buy | Buy |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- westpharma.com
News
- What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
- Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494
- TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500
- Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500
- Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480
- West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
- West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
- Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics
- West Pharmaceutical Servs Q3 2026 Earnings Call Transcript
- West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
Your note
Sign in to keep a note on WST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRKETT BERNARD JOHN | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 17, 2025 | 7,520 |
| BUTHMAN MARK A | Director | Stock Award(Grant) | May 3, 2026 | 44,308 |
| FAVORITE ANNETTE F | Officer | Sale | Sep 14, 2026 | 21,817 |
| FEEHERY WILLIAM F. | Director | Stock Award(Grant) | May 3, 2026 | 32,519 |
| GREEN ERIC MARK | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 175,418 |
| HOFMANN THOMAS W | Director | Stock Award(Grant) | May 5, 2025 | 44,637 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.55% | 6,651,784 | 2.71B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.62% | 4,613,134 | 1.88B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.76% | 4,015,766 | 1.64B | Jun 29, 2026 |
| FMR, LLC | 5.13% | 3,574,816 | 1.46B | Jun 29, 2026 |
| State Street Corporation | 4.81% | 3,348,698 | 1.37B | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 3.46% | 2,411,792 | 983.91M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 2,242,860 | 915.00M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.63% | 1,830,358 | 746.71M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.20% | 1,530,738 | 624.48M | Jun 29, 2026 |
| Fidelity Contrafund | 1.61% | 1,120,323 | 457.05M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 1.35% | 940,525 | 383.70M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.35% | 937,921 | 382.63M | Sep 29, 2026 |